That oncologists do not tell their patients

That oncologists do not tell their patients

PHARMACOGENOMICS

One of the most important elements of personalized medicine is pharmacogenomics, the study of genetic variations that influence individual response to drugs. Enzymes responsible for drug metabolism and proteins that determine the cellular response to drugs (receivers) are encoded by genes, and therefore can be variable in the expression, activity level and function when genetic variations are present. Whether a patient has one of these variations can help health care professionals individualize drug therapy, reduce the number of adverse drug reactions and increase efficacy. Pharmacogenomics has been characterized as "getting the right dose of the right drug to the right patient at the right time."

BACKGROUND

Chemotherapeutic agents are considered one of the categories of the most dangerous drugs. Currently, drugs are delivered based on the body of his area or BSA patients. This approach, however, does not take into account the variation of a patient in drug metabolism and can cause serious adverse drug reactions.

Accredited laboratories understand the complexity of chemotherapy, the variety of drugs available, and the challenges patients and providers are facing.

Our tests (TMP) Oncology Pharmacogenetics panel is designed to help physicians better understand a patient's ability to metabolize drugs commonly used in treatments against cancer.

Results PGT help personalized medicine physician practice the right drug at the right dose to the right patient and achieve the best result of treatment. PGT also helps boost medication adherence, reduce adverse drug reactions, drug interactions to avoid, reduce medical costs, and most importantly, saving valuable drug trial and error time.

ONCOLOGY PANEL

PGT panels can help doctors decide the best treatment for the cancer itself and symptoms associated with cancer treatments, such as pain, nausea and loss of appetite.

CANDIDATES FOR ONCOLOGY PANEL PGT

· Several problems of organ system

· Multiple Drugs

· Serious Adverse Drug Reaction

Cytochrome P450 enzymes

Enzymes cytochrome P450 (CYP) expressed predominantly in the liver, are responsible for metabolizing approximately 75% of all drugs. PGT detect single nucleotide polymorphism (SNP) in five genes for these enzymes - CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and.

Laboratory results are reported as poor metabolizers (PM), intermediate metabolizer (IM) metabolizer (EM), and ultra-fast metabolizers (UM) for their different degrees of drug metabolizing capacity. Medications can be adjusted to obtain the best results from treatment.

ONCOLOGY TYPE PANEL

Gene: CYP2C9

Clinical use:

Anti-cancer drug

cyclophosphamide

Anti-nausea and appetite stimulant

dronabinol (tetrahydrocannabinol)

Gene: CYP2C19

Clinical use:

Anti-cancer drug

Tamoxifen

Anti-nausea and appetite stimulant

dronabinol (tetrahydrocannabinol)

Gene: CYP2D6

Clinical use:

Anti-stimulant

mirtazapine

Anti-nausea medications

metoclopramide, ondansetron, prochlorperazine

Gene: CYP3A4, CYP3A5

Clinical use:

Anti-cancer drugs

docetaxel, imatinib, etoposide, ifofamide, irinotecan, paclitaxel,

tamoxifen, topotecan, vinblastine, vincristine, vinorelbine

Anti-nausea medications

dronabinol, ondansetron, granisetron, prochlorperazine

appetite stimulants

mirtazapine, dronabinol, dexamethasone, prednisone

methylprednisolone, megestrol acetate

Since this is a relatively new test outside environments such as the Mayo Clinic and Vanderbilt, patients are encouraged to ask their personal physician to request such tests.